{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:18:43Z","timestamp":1782548323610,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"am","delay-in-days":276,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010739","name":"Universit\u00e0 degli Studi di Camerino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA014351"],"award-info":[{"award-number":["AA014351"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01DA45300"],"award-info":[{"award-number":["U01DA45300"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neuropharm.2024.110048","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T16:11:21Z","timestamp":1718727081000},"page":"110048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-8679","authenticated-orcid":false,"given":"Nazzareno","family":"Cannella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Lunerti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Benvenuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Soverchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-6058","authenticated-orcid":false,"given":"Friedbert","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110048_bib1","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00097-8","article-title":"Guidelines and methodological reviews concerning drug abuse liability assessment","volume":"70","author":"Balster","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2024.110048_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbr.2009.11.030","article-title":"Yohimbine stress potentiates conditioned cue-induced reinstatement of heroin-seeking in rats","volume":"208","author":"Banna","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110048_bib3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2024.110048_bib4","first-page":"342","article-title":"Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options","volume":"104","author":"Bonhomme","year":"2012","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2024.110048_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(00)00590-2","article-title":"Effect of nociceptin\/orphanin FQ on the rewarding properties of morphine","volume":"404","author":"Ciccocioppo","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110048_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.biopsych.2006.01.006","article-title":"Buprenorphine reduces alcohol drinking through activation of the nociceptin\/orphanin FQ-NOP receptor system","volume":"61","author":"Ciccocioppo","year":"2007","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110048_bib8","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/s41386-022-01363-9","article-title":"Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies","volume":"47","author":"Curley","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110048_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/ALN.0000000000001529","article-title":"Respiratory effects of the nociceptin\/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers","volume":"126","author":"Dahan","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2024.110048_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-016-4452-1","article-title":"Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents","volume":"234","author":"de Guglielmo","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110048_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.117.241042","article-title":"Cebranopadol blocks the escalation of cocaine intake and conditioned reinstatement of cocaine seeking in rats","volume":"362","author":"de Guglielmo","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110048_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/ALN.0000000000003848","article-title":"Functional profile of systemic and intrathecal cebranopadol in nonhuman primates","volume":"135","author":"Ding","year":"2021","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2024.110048_bib13","first-page":"25","article-title":"Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine","volume":"262","author":"Frances","year":"1992","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110048_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0000000000000995","article-title":"Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: a phase 1 randomized controlled study","volume":"39","author":"Gohler","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.110048_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00213-012-2868-9","article-title":"Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals","volume":"225","author":"Greenwald","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110048_bib16","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors - improved analgesics with reduced side effects?","volume":"175","author":"Gunther","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110048_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2024.110048_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/adb.12513","article-title":"Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption","volume":"23","author":"Kallupi","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2024.110048_bib19","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/jpet.110.175620","volume":"336","author":"Khroyan","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110048_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrd897","article-title":"Pharmacotherapy of addictions","volume":"1","author":"Kreek","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2024.110048_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/bja\/aeu332","article-title":"Cebranopadol: a first in-class example of a nociceptin\/orphanin FQ receptor and opioid receptor agonist","volume":"114","author":"Lambert","year":"2015","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2024.110048_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1021\/cn300124f","article-title":"The therapeutic potential of nociceptin\/orphanin FQ receptor agonists as analgesics without abuse liability","volume":"4","author":"Lin","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110048_bib23","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0376-8716(03)00059-0","article-title":"Clinical efficacy of buprenorphine: comparisons to methadone and placebo","volume":"70","author":"Ling","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2024.110048_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110048_bib25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ALN.0000000000001530","article-title":"Opioid-type respiratory depressant side effects of cebranopadol in rats are limited by its nociceptin\/orphanin FQ peptide receptor agonist activity","volume":"126","author":"Linz","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2024.110048_bib26","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","article-title":"Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors","volume":"23","author":"Lutfy","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110048_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0091-3057(97)00599-6","article-title":"Training dose and session time as contextual determinants of heroin self-administration in rats","volume":"60","author":"Martin","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2024.110048_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2024.110048_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences","volume":"25","author":"Megarbane","year":"2006","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.neuropharm.2024.110048_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.7352279","article-title":"Buprenorphine suppresses heroin use by heroin addicts","volume":"207","author":"Mello","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2024.110048_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clpt.2003.09.004","article-title":"Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence","volume":"75","author":"Montoya","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2024.110048_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0006-8993(99)01425-0","article-title":"Orphanin FQ\/nociceptin blocks acquisition of morphine place preference","volume":"832","author":"Murphy","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110048_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2165\/00023210-200620090-00001","article-title":"Buprenorphine-containing treatments: place in the management of opioid addiction","volume":"20","author":"Robinson","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2024.110048_bib34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/ml500116x","article-title":"Discovery of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as potent NOP and opioid receptor agonists","volume":"5","author":"Schunk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2024.110048_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/ml500117c","article-title":"Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol","volume":"5","author":"Schunk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2024.110048_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2009.07.028","article-title":"Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking","volume":"1314","author":"Shalev","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110048_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fpsyt.2017.00234","article-title":"Cebranopadol, a mixed opioid agonist, reduces cocaine self-administration through nociceptin opioid and mu opioid receptors","volume":"8","author":"Shen","year":"2017","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110048_bib38","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.npp.1300712","article-title":"Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement","volume":"30","author":"Sorge","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110048_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00213-006-0485-1","article-title":"The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration","volume":"188","author":"Sorge","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110048_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2014.10.029","article-title":"Effects of the NOP agonist SCH2 21510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats","volume":"745","author":"Sukhtankar","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110048_bib41","first-page":"7451","article-title":"The use of bifunctional NOP\/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders","volume":"19","author":"Toll","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2024.110048_bib42","first-page":"547","article-title":"Intravenous self-administration of drugs in rats","volume":"204","author":"van Ree","year":"1978","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110048_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110048_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00008877-199603000-00006","article-title":"Effects of buprenorphine on behaviour maintained by heroin and alfentanil in rhesus monkeys","volume":"7","author":"Winger","year":"1996","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110048_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/mol.56.2.334","article-title":"Agonistic effect of buprenorphine in a nociceptin\/OFQ receptor-triggered reporter gene assay","volume":"56","author":"Wnendt","year":"1999","journal-title":"Mol. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400217X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400217X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:59:52Z","timestamp":1728295192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082400217X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":44,"alternative-id":["S002839082400217X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110048","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110048"}}